Girish Venkataraman to Tumor Suppressor Protein p53
This is a "connection" page, showing publications Girish Venkataraman has written about Tumor Suppressor Protein p53.
Connection Strength
3.359
-
Characterization of chromosome 5 aberrations in TP53 mutated myeloid neoplasms with =5% blasts: An International TP53 Investigators Network (iTiN) study. Cancer. 2026 Jan 01; 132(1):e70210.
Score: 0.762
-
Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
Score: 0.743
-
Somatic co-alteration signatures are prognostic in high-grade TP53-mutated myeloid neoplasms. Br J Haematol. 2025 Apr; 206(4):1103-1108.
Score: 0.705
-
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
Score: 0.685
-
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults. Blood Cancer J. 2025 Aug 14; 15(1):138.
Score: 0.186
-
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression. Leuk Lymphoma. 2022 11; 63(11):2735-2738.
Score: 0.149
-
Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study. Genes Chromosomes Cancer. 2020 08; 59(8):484-494.
Score: 0.128